EVOFEM BIOSCIENCES, INC. Proceeds from Convertible Debt
EVOFEM BIOSCIENCES, INC. (EVFM) reported Proceeds from Convertible Debt of $25.00 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-24.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromConvertibleDebt · last filed 2025-03-24
- EVOFEM BIOSCIENCES, INC. proceeds from convertible debt for the quarter ending 2024-12-31 was $0.00.
- EVOFEM BIOSCIENCES, INC. proceeds from convertible debt for the quarter ending 2024-09-30 was $0.00.
- EVOFEM BIOSCIENCES, INC. proceeds from convertible debt for the quarter ending 2023-12-31 was $0.00.
- EVOFEM BIOSCIENCES, INC. proceeds from convertible debt for the quarter ending 2023-09-30 was $0.00.
- EVOFEM BIOSCIENCES, INC. proceeds from convertible debt for fiscal 2024 was $25.00M, a 0.00% change from fiscal 2023.
- EVOFEM BIOSCIENCES, INC. proceeds from convertible debt for fiscal 2023 was $25.00M.
- EVOFEM BIOSCIENCES, INC. proceeds from convertible debt for fiscal 2020 was $25.00M.
| Period end | Proceeds from Convertible Debt 3 month | Proceeds from Convertible Debt 6 month | Proceeds from Convertible Debt 9 month | Proceeds from Convertible Debt 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $0.00 derived: sum of 2 quarters · filed 2025-03-24 | $25.00M 10-K · filed 2025-03-24 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $25.00M 10-Q · filed 2024-11-14 | ||
| 2024-06-30 | $25.00M 10-Q · filed 2024-08-14 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $0.00 derived: sum of 2 quarters · filed 2024-03-27 | $0.00 derived: sum of 3 quarters · filed 2024-03-27 | $25.00M 10-K · filed 2024-03-27 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $0.00 derived: sum of 2 quarters · filed 2023-11-14 | $25.00M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $25.00M 10-Q · filed 2023-08-14 | ||
| 2023-03-31 | $25.00M 10-Q · filed 2024-05-15 | |||
| 2021-03-31 | $25.00M 10-Q · filed 2021-05-06 | $50.00M derived: sum of 2 quarters · filed 2023-04-27 | ||
| 2020-12-31 | $25.00M 10-K · filed 2023-04-27 | $25.00M 10-K · filed 2021-03-04 |